Spontaneous disappearance of viral replication and liver cell inflammation in HBsAg‐positive chronic active hepatitis: Results of a placebo vs. interferon trial
Solko W. Schalm, Rudolf A. Heijtink – 1 November 1982 – In 20 patients with HBsAg‐and HBeAg‐positive chronic active hepatitis, we determined the long‐term effect of human leukocyte interferon as well as placebo treatment. During the 2‐year follow‐up period, HBsAg remained present in all patients, but the Dane particle markers HBeAg and DNA polymerase disappeared in two of 10 patients who had received interferon, and in 4 of 10 patients from the placebo group.